Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM.

Cancer Res. 2013 Jan 15;73(2):824-33. doi: 10.1158/0008-5472.CAN-12-1611. Epub 2012 Nov 20.

2.

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F.

Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review.

PMID:
18393776
3.

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

Karamouzis MV, Grandis JR, Argiris A.

JAMA. 2007 Jul 4;298(1):70-82. Review.

PMID:
17609492
4.
5.

EGFR-targeted therapeutics: focus on SCCHN and NSCLC.

Sattler M, Abidoye O, Salgia R.

ScientificWorldJournal. 2008 Sep 21;8:909-19. doi: 10.1100/tsw.2008.117. Review.

6.

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Agulnik M.

Med Oncol. 2012 Dec;29(4):2481-91. doi: 10.1007/s12032-012-0159-2. Epub 2012 Jan 18. Review.

7.

Epidermal growth factor receptor inhibition strategies in oncology.

Harari PM.

Endocr Relat Cancer. 2004 Dec;11(4):689-708. Review.

9.

Epidermal growth factor receptor targeted therapies for solid tumours.

Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP.

Acta Clin Belg. 2011 Jan-Feb;66(1):10-7. Review.

PMID:
21485758
10.

Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.

Sharafinski ME, Ferris RL, Ferrone S, Grandis JR.

Head Neck. 2010 Oct;32(10):1412-21. doi: 10.1002/hed.21365. Review.

11.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
12.

Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.

Saba NF, Khuri FR, Shin DM.

Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim. Review.

13.

Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges.

Cappuzzo F, Toschi L, Finocchiaro G, Ligorio C, Santoro A.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S10-23. Review.

PMID:
17520577
14.

Skin toxicities associated with epidermal growth factor receptor inhibitors.

Li T, Perez-Soler R.

Target Oncol. 2009 Apr;4(2):107-19. doi: 10.1007/s11523-009-0114-0. Epub 2009 May 19. Review.

PMID:
19452131
15.

EGFR-targeting monoclonal antibodies in head and neck cancer.

Astsaturov I, Cohen RB, Harari PM.

Curr Cancer Drug Targets. 2006 Dec;6(8):691-710. Review.

PMID:
17168674
16.

The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.

Gaffney DC, Soyer HP, Simpson F.

Australas J Dermatol. 2014 Feb;55(1):24-34. doi: 10.1111/ajd.12025. Epub 2013 Feb 21. Review.

PMID:
23425099
17.

Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, Lardon F.

Oncologist. 2013;18(7):850-64. doi: 10.1634/theoncologist.2013-0013. Epub 2013 Jul 2. Review.

18.

Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.

Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE.

Expert Rev Anticancer Ther. 2016 Aug;16(8):847-58. doi: 10.1080/14737140.2016.1202116. Epub 2016 Jul 11. Review.

PMID:
27400139
19.

Treatment of advanced head and neck cancer with cetuximab.

Merlano M, Garrone O.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S71-6. Review.

PMID:
17520584
20.

Epithelial growth factor receptor interacting agents.

Baselga J, Albanell J.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63. Review.

PMID:
12512382

Supplemental Content

Support Center